Caroline Seymour

Ripretinib demonstrated promising antitumor activity and was found to be well tolerated in patients with refractory advanced gastrointestinal stromal tumor.

Bradley McGregor, MD, discusses some of the recent approaches that have emerged in bladder cancer and renal cell carcinoma, as well as anticipated developments in each field.

Tipifarnib demonstrated encouraging antitumor activity in patients with recurrent and metastatic head and neck cancer with high HRAS-mutant variant allele frequency, surpassing historical competitors in the second- or later-line settings.

Nilanjan Ghosh, MD, PhD, discusses the role of BTK inhibitors in B-cell malignancies and ongoing research with each agent.

Jordan D. Berlin, MD, discusses the importance of more data and more effective treatment regimens in metastatic pancreatic cancer, despite the number of treatment options currently available.

The interim futility review for the phase 2 HopES Sarcoma trial was positive and will continue to evaluate SM-88 for patients with Ewing sarcoma and other high-risk sarcomas.

Patients with a suspected or diagnosed myeloproliferative neoplasm should undergo targeted next-generation sequencing versus sequential or allele specific testing to reduce the risk of identifying a false driver mutation or an excluded diagnosis of MPN.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses immunotherapy, PARP inhibitors, and antibody-drug conjugates, which have become pillars of treatment in triple-negative breast cancer.

Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.

John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the risk of late recurrence in early breast cancer, current approaches to extended adjuvant endocrine therapy, and ongoing research evaluating assays aimed at capturing both the risk of late recurrence and benefit from extended endocrine therapy.

Vamsidhar Velcheti, MD, discusses the current and emerging treatment options for patients with ALK- and ROS1-positive non–small cell lung cancer.

Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer.

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.

Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Joshua K. Sabari, MD, discusses a number of immunotherapy regimens that have emerged in the frontline setting for patients with driver-negative advanced non–small cell lung cancer; however, for many patients, the decision comes down to pembrolizumab monotherapy or pembrolizumab in combination with platinum-doublet chemotherapy.

The administration of luteinizing hormone-releasing hormone agonists in patients with prostate cancer was significantly more delayed in clinical practice than in pivotal clinical trials.

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

Treatment with tocilizumab does not appear to inhibit the induction of anti-SARS-CoV-2 antibodies in patients with severe coronavirus disease 2019.

Noopur S. Raje, MD, discusses some of the most noteworthy research presented at the 2020 ASCO Virtual Scientific Program and the 2020 European Hematology Association Congress in multiple myeloma.

The National Comprehensive Cancer Network recently published updated Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma, listing pexidartinib as a systemic treatment for patients with tenosynovial giant cell tumor.

Charles E. Geyer, Jr, MD, discusses the state of HER2-positive breast cancer, the significance of the results of the DESTINY-Breast01 trial, and symptoms that could be an early indicator of interstitial lung disease.

William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.

Despite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.

A panel of experts in acute myeloid leukemia (AML) consider potential treatment options for patients with AML

The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.

Matthew Schabath, PhD, discusses the use of peritumoral and intratumoral radiomic features, where investigators created a model that identified patients with early-stage lung cancer at high risk of experiencing poor survival outcomes.

Paul A. Bunn, Jr, MD, discusses how fam-trastuzumab deruxtecan-nxki could provide patients with metastatic non–small cell lung cancer who harbor HER2 exon 20 insertion mutations and high HER2 expression a more specific and less toxic treatment compared with platinum doublet chemotherapy.

Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.